Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Acquires IP Related to miR-21 Modulation

Premium

Regulus Therapeutics this week announced that it has acquired from the University of Wuerzburg the exclusive rights to intellectual property covering methods for modulating microRNA-21.

According to the company, the miRNA has been shown to be dysregulated in mouse models of cardiac disease and fibrosis, and "antagonizing miR-21 with therapeutic oligonucleotides … inhibits fibrosis and attenuates cardiac function in such models."

Regulus, which is a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, is currently developing an miR-21-targeting drug as an anti-fibrotic agent.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.